All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage IIIa stage IIIb stage IIIc stage M0/M1A/M1B stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
melanoma (ML), Ipilimumab (10 mg/kg) vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.84 [0.71; 1.00]
CheckMate 238, 2017 (REV) 1.15 [0.87; 1.51]
EORTC 18071, 2015 0.72 [0.58; 0.89]
0.87 [0.69 ; 1.10 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 72% 2,584 low not evaluable deaths (OS) (extension)detailed results EORTC 18071, 2015 0.73 [0.64; 0.83]
0.73 [0.64 ; 0.83 ] EORTC 18071, 2015 1 0% 951 NA not evaluable MFSdetailed results CheckMate 238, 2017 (REV) 1.37 [1.04; 1.80]
EORTC 18071, 2015 0.76 [0.63; 0.91]
1.01 [0.57 ; 1.80 ] CheckMate 238, 2017 (REV), EORTC 18071, 2015 2 92% 1,686 low not evaluable MFS (extension)detailed results EORTC 18071, 2015 0.76 [0.64; 0.90]
0.76 [0.64 ; 0.90 ] EORTC 18071, 2015 1 0% 951 NA not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.89 [0.66; 1.21]
0.89 [0.66 ; 1.21 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable RFS (extension)detailed results CheckMate 238, 2017 (REV) 1.41 [1.18; 1.69]
EORTC 18071, 2015 0.75 [0.63; 0.89]
1.03 [0.55 ; 1.90 ] CheckMate 238, 2017 (REV), EORTC 18071, 2015 2 96% 1,857 low not evaluable RFS/DFSdetailed results CheckMate 238, 2017 (REV) 1.54 [1.21; 1.96]
EORTC 18071, 2015 0.75 [0.63; 0.89]
1.07 [0.53 ; 2.16 ] CheckMate 238, 2017 (REV), EORTC 18071, 2015 2 96% 1,857 low not evaluable DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.19 [0.86; 1.63]
1.19 [0.86 ; 1.63 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable objective responses (ORR)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.31 [0.86; 2.00]
1.31 [0.86 ; 2.00 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable AE (any grade)detailed results CheckMate 238, 2017 (REV) 2.04 [0.81; 5.09]
EORTC 18071, 2015 7.53 [3.17; 17.90]
3.95 [1.10 ; 14.25 ] CheckMate 238, 2017 (REV), EORTC 18071, 2015 2 76% 1,850 low not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 3.61 [2.72; 4.78]
EORTC 18071, 2015 0.11 [0.08; 0.17]
0.64 [0.02 ; 18.93 ] CheckMate 238, 2017 (REV), EORTC 18071, 2015 2 100% 1,850 low not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 (REV) 6.88 [4.79; 9.89]
6.88 [4.79 ; 9.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 (REV) 9.18 [5.67; 14.85]
9.18 [5.67 ; 14.85 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.40 [1.76; 3.28]
CheckMate 238, 2017 (REV) 3.98 [2.35; 6.74]
EORTC 18071, 2015 14.40 [10.07; 20.60]
5.16 [1.59 ; 16.78 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 96% 2,576 low not evaluable TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.70 [1.86; 3.92]
CheckMate 238, 2017 (REV) 5.05 [3.67; 6.97]
EORTC 18071, 2015 25.27 [14.14; 45.18]
6.84 [2.37 ; 19.72 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 95% 2,576 low not evaluable TRAE leading to death (grade 5)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.00 [0.36; 10.99]
CheckMate 238, 2017 (REV) 4.00 [0.18; 89.05]
EORTC 18071, 2015 10.16 [0.55; 186.52]
3.19 [0.84 ; 12.04 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 0% 2,576 low not evaluable TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.97 [1.40; 2.78]
CheckMate 238, 2017 (REV) 8.53 [5.76; 12.63]
EORTC 18071, 2015 21.35 [13.41; 33.97]
7.06 [1.79 ; 27.86 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 97% 2,576 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.27 [1.53; 3.38]
CheckMate 238, 2017 (REV) 11.69 [6.83; 20.02]
5.10 [1.02 ; 25.41 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 96% 1,631 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.07; 59.70]
2.00 [0.07 ; 59.70 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 238, 2017 (REV) 2.00 [0.37; 11.00]
2.00 [0.44 ; 9.17 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.18; 22.14]
2.00 [0.18 ; 22.14 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 4.02 [0.45; 36.09]
4.02 [0.45 ; 36.09 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.16 [0.96; 4.84]
EORTC 18071, 2015 39.14 [5.34; 286.74]
7.92 [0.47 ; 133.48 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, EORTC 18071, 2015 2 86% 1,671 low not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 0.50 [0.02; 14.89]
0.50 [0.02 ; 14.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.84 [1.05; 3.21]
CheckMate 238, 2017 (REV) 6.67 [2.97; 14.99]
EORTC 18071, 2015 25.54 [6.16; 105.87]
5.99 [1.52 ; 23.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 87% 2,576 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.30 [0.99; 5.36]
EORTC 18071, 2015 42.70 [5.84; 312.15]
8.58 [0.50 ; 148.05 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, EORTC 18071, 2015 2 86% 1,671 low not evaluable Eye disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.37; 11.00]
2.00 [0.37 ; 11.00 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.82 [1.14; 2.91]
CheckMate 238, 2017 (REV) 9.92 [4.91; 20.07]
EORTC 18071, 2015 22.61 [8.20; 62.34]
7.08 [1.54 ; 32.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 93% 2,576 low not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 7.08 [0.87; 57.77]
7.08 [0.87 ; 57.77 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
2.51 [0.48 ; 13.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 (REV) 6.73 [3.15; 14.39]
EORTC 18071, 2015 57.44 [7.90; 417.44]
16.04 [2.04 ; 126.16 ] CheckMate 238, 2017 (REV), EORTC 18071, 2015 2 74% 1,850 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.01 [0.30; 120.38]
CheckMate 238, 2017 (REV) 0.50 [0.02; 14.89]
1.98 [0.17 ; 22.37 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 14% 1,631 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 1.00 [0.06; 16.00]
1.00 [0.06 ; 16.00 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.43 [0.54; 3.81]
CheckMate 238, 2017 (REV) 5.60 [1.23; 25.41]
EORTC 18071, 2015 44.19 [2.67; 732.31]
4.76 [0.91 ; 24.98 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 68% 2,576 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 238, 2017 (REV) 2.00 [0.18; 22.14]
2.00 [0.28 ; 14.21 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.11 [1.01; 65.20]
CheckMate 238, 2017 (REV) 9.85 [2.28; 42.54]
9.24 [2.79 ; 30.59 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.14 [1.36; 27.62]
CheckMate 238, 2017 (REV) 5.44 [2.07; 14.31]
5.64 [2.50 ; 12.71 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 238, 2017 (REV) 18.30 [1.06; 316.70]
7.32 [0.82 ; 65.03 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 0.50 [0.02; 14.89]
0.50 [0.02 ; 14.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
EORTC 18071, 2015 18.45 [1.07; 319.15]
12.34 [1.59 ; 95.62 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, EORTC 18071, 2015 2 0% 1,671 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.99 [0.14; 7.10]
CheckMate 238, 2017 (REV) 10.08 [0.55; 185.02]
2.44 [0.27 ; 22.33 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 40% 1,631 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 4.00 [0.18; 89.05]
4.00 [0.18 ; 89.05 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CheckMate 238, 2017 (REV) 2.85 [1.02; 7.98]
EORTC 18071, 2015 10.16 [0.55; 186.52]
3.06 [1.33 ; 7.07 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 0% 2,576 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 (REV) 1.00 [0.02; 50.40]
1.00 [0.02 ; 50.40 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
CheckMate 238, 2017 (REV) 8.04 [0.42; 152.61]
8.04 [1.00 ; 64.42 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV) 2 0% 1,631 low not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.40 [0.44; 4.45]
CheckMate 238, 2017 (REV) 5.67 [2.16; 14.85]
EORTC 18071, 2015 42.00 [2.53; 697.02]
4.67 [1.08 ; 20.14 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 (REV), EORTC 18071, 2015 3 68% 2,576 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Uveitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Abdominal pain AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.17]
0.04 [0.01 ; 0.17 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Colitis AE (grade 3-4)detailed results EORTC 18071, 2015 6.26 [2.61; 15.03]
6.26 [2.61 ; 15.03 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Cough AE (grade 3-4)detailed results Out of scale EORTC 18071, 2015 0.01 [0.00; 0.15]
0.01 [0.00 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Decreased appetite AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.01; 0.46]
0.06 [0.01 ; 0.46 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Diarrhoea AE (grade 3-4)detailed results EORTC 18071, 2015 0.26 [0.18; 0.37]
0.26 [0.18 ; 0.37 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Fatigue AE (grade 3-4)detailed results EORTC 18071, 2015 0.05 [0.03; 0.10]
0.05 [0.03 ; 0.10 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Headache AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.11]
0.04 [0.01 ; 0.11 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypophysitis AE (grade 3-4)detailed results EORTC 18071, 2015 11.01 [2.57; 47.24]
11.01 [2.57 ; 47.24 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.02; 1.16]
0.14 [0.02 ; 1.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increase AST AE (grade 3-4)detailed results EORTC 18071, 2015 0.80 [0.45; 1.45]
0.80 [0.45 ; 1.45 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increased ALT AE (grade 3-4)detailed results EORTC 18071, 2015 0.97 [0.55; 1.70]
0.97 [0.55 ; 1.70 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Nausea AE (grade 3-4)detailed results EORTC 18071, 2015 0.01 [0.00; 0.07]
0.01 [0.00 ; 0.07 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pruritus AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.07; 0.26]
0.14 [0.07 ; 0.26 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pyrexia AE (grade 3-4)detailed results EORTC 18071, 2015 0.21 [0.08; 0.56]
0.21 [0.08 ; 0.56 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Rash AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.03; 0.15]
0.06 [0.03 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Vomiting AE (grade 3-4)detailed results EORTC 18071, 2015 0.07 [0.02; 0.29]
0.07 [0.02 ; 0.29 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Weight decreased AE (grade 3-4)detailed results EORTC 18071, 2015 0.02 [0.00; 0.16]
0.02 [0.00 ; 0.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-23 09:35 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 2,283,284,70,235,285,68,127,128,286,69,129
- treatments: 558
